| 000 | 01098 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250518024558.0 | ||
| 264 | 0 | _c20200316 | |
| 008 | 202003s 0 0 eng d | ||
| 022 | _a1744-8042 | ||
| 024 | 7 |
_a10.2217/pgs-2018-0191 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCunningham, Patrick N | |
| 245 | 0 | 0 |
_aThe future of pharmacogenetics in the treatment of hypertension. _h[electronic resource] |
| 260 |
_bPharmacogenomics _c02 2019 |
||
| 300 |
_a129-132 p. _bdigital |
||
| 500 | _aPublication Type: Editorial | ||
| 650 | 0 | 4 |
_aAdrenergic beta-Antagonists _xadverse effects |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xadverse effects |
| 650 | 0 | 4 |
_aBlood Pressure _xgenetics |
| 650 | 0 | 4 |
_aCalcium Channel Blockers _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xdrug therapy |
| 650 | 0 | 4 |
_aPharmacogenetics _xtrends |
| 650 | 0 | 4 |
_aPolymorphism, Single Nucleotide _xgenetics |
| 700 | 1 | _aChapman, Arlene B | |
| 773 | 0 |
_tPharmacogenomics _gvol. 20 _gno. 3 _gp. 129-132 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/pgs-2018-0191 _zAvailable from publisher's website |
| 999 |
_c29415847 _d29415847 |
||